Coherus Oncology (CHRS) EBT Margin (2013 - 2026)
Coherus Oncology (CHRS) posted EBT Margin of 300.04% for Q1 2026, up 17.47% sequentially from 363.56% in Q4 2025, and up 32370.0% YoY from N/an in Q1 2025.
Coherus Oncology (CHRS) EBT Margin (2013 - 2026) Analysis & Trends
Coherus Oncology has reported EBT Margin for 13 years, with the latest figure at 300.04% in Q1 2026.
- Quarterly EBT Margin rose 32370.0% year-over-year to 300.04% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 368.28% (up 25022.0% YoY) and the FY2025 annual result came in at 434.23%, up 38200.0% from the prior year.
- EBT Margin grew to 300.04% in Q1 2026 per CHRS's latest filing, from 363.56% in the prior quarter.
- Over five years, EBT Margin peaked at 53.67% in Q3 2023 and troughed at 2947.83% in Q1 2024.
- A 5-year average of 469.63% and a median of 300.04% in 2026 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2024 and 2025: EBT Margin tumbled 271436 bps in 2024, then soared 232409 bps in 2025.
- Over 5 years, EBT Margin stood at 129.81% in 2022, then surged by 33 bps to 87.03% in 2023, then tumbled by 585 bps to 596.06% in 2024, then surged by 39 bps to 363.56% in 2025, then rose by 17 bps to 300.04% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 300.04%, 363.56%, and 384.73% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.77% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -2.67% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -25.06% |
| 10 | Coherus Oncology | 203.82 Mn | 98.51 Mn | 10.07 Mn | -233.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -233.08% |
| Mar 31, 2026 | -300.04% |
| Dec 31, 2025 | -363.56% |
| Sep 30, 2025 | -384.73% |
| Jun 30, 2025 | -437.51% |
| Mar 31, 2025 | -623.74% |
| Dec 31, 2024 | -596.06% |
| Sep 30, 2024 | -786.50% |
| Jun 30, 2024 | -532.74% |
| Mar 31, 2024 | -2,947.83% |
| Dec 31, 2023 | -87.03% |
| Sep 30, 2023 | -53.67% |
| Jun 30, 2023 | -73.01% |
| Mar 31, 2023 | -233.47% |
| Dec 31, 2022 | -129.81% |
| Sep 30, 2022 | -190.76% |
| Jun 30, 2022 | -83.37% |
| Mar 31, 2022 | -159.83% |
| Dec 31, 2021 | -62.28% |
| Sep 30, 2021 | -46.70% |